Purpose PET using radiolabelled amino acids has become a promising tool in the diagnostics of gliomas and brain metastasis. Current research is focused on the evaluation of amide proton transfer (APT) chemical exchange saturation transfer (CEST) MR imaging for brain tumour imaging. In this hybrid MR-PET study, brain tumours were compared using 3D data derived from APT-CEST MRI and amino acid PET using O-(2-
Introduction
The diagnostics of brain tumours, particularly in pre-treated patients, remains unsatisfactory despite the availability of high-resolution morphological imaging with conventional magnetic resonance imaging (MRI) [1] . In order to improve diagnostic accuracy, multiple imaging modalities have been combined, such as advanced MRI and positron emission tomography (PET), to provide more detailed information and metabolic information. Information about amino acid transport, acquired with PET, has become an important and complementary tool to standard MRI and can potentially be used to define biological tumour volume for treatment planning, treatment monitoring and recurrence evaluation [2] [3] [4] [5] [6] [7] [8] [9] . Several amino acid tracers are available, including L-[methyl- However, fluorine-18-labelled radiotracers are preferred due to the logistical advantages of the longer half-life. Furthermore, 18 F-FET exhibits different tracer kinetics depending on the tumour grade when compared to 18 F-FDOPA or 11 C-MET [4] . Chemical exchange saturation transfer (CEST) is an MRI technique that enables the indirect detection of metabolites using the MR-free water signal [10] . CEST is based on the phenomenon of transferring saturation from a solute pool (metabolites) to the water pool, resulting in contrast that is dependent on metabolite concentration and its proton exchange rate [11, 12] . Repeating the measurements at different saturation frequencies allows the acquisition of the Z-spectrum, where the contrast of multiple metabolites is encoded. This technique has many applications including the measurement of glycogen (GlycoCEST) [13] , glutamate (GluCEST) [14] , glucose (GlucoCEST) [15] and amide proton transfer (APT) [16] . Moreover, CEST contrast is also pH-dependent [16] [17] [18] [19] . APT-CEST, which provides information at 3.5 ppm downfield from water, has been shown to allow differentiation between low-and high-grade gliomas [20, 21] . In addition, APT-CEST has shown potential to distinguish between recurrent tumour and radiation necrosis [22, 23] . Furthermore, studies have reported that the signals from the upfield nuclear Overhauser effect (NOE) at −3.5 ppm were also presented as a unique contrast in gliomas at 7 T [24] [25] [26] .
The introduction of hybrid MR-PET scanners promotes the synergy between both modalities by allowing the simultaneous acquisition of human MRI and PET data [27] . However, to the best of our knowledge, no study in the literature has compared amino acid PET of brain tumours with APT-CEST using simultaneous MR-PET. Although, initial attempts to compare CEST signals from amine and 18 F-FDOPA using nonsimultaneous measurements have recently been reported [28, 29] . This is the first study to investigate simultaneous MR-PET brain tumour imaging using APT-CEST and 18 F-FET PET.
Here, we present a methodology to obtain volumetric APT-CEST and 18 F-FET PET to study brain tumours using simultaneous MR-PET. We compare CEST imaging with the more clinically established 18 F-FET PET to explore the similarities between both imaging modalities.
Materials and methods

Measurement details
Subjects
Eight patients with suspected cerebral glioma were included in this feasibility study (four female, four male; median age: 56 years; age range: 20-69 years). All subjects presented increased 18 F-FET uptake in the tumour, which was defined as 18 F-FET uptake of at least 1.6 times the uptake of healthy brain tissue of the same subject [30] . Seven subjects presented a single 18 F-FET-positive region and one subject presented two 18 F-FET-positive regions. Detailed information on the patient group is given in Table 1 . The university ethics committee and the relevant federal authorities approved the study. All subjects provided written informed consent for their participation, prior to the study.
Instrumentation
Measurements were performed in a hybrid 3-T MR-BrainPET scanner (MAGNETOM Trio, Siemens Healthineers, Erlangen, Germany) equipped with a dedicated BrainPET with a spatial resolution of approximately 3 mm full width at half maximum (FWHM) in the centre [31] . The BrainPET is inserted in a MAGNETOM Trio 3-T MR machine. A dedicated MR head coil was used, which is composed of an outer 
MR acquisitions
In the clinical protocol, CEST measurements were performed before the injection of the MR contrast agent. The clinical protocol included a T 1 -weighted magnetisation-prepared rapid gradient echo (MPRAGE) sequence and a T 2 -weighted fluid-attenuated inversion recovery sequence (FLAIR). A contrast-enhanced MPRAGE sequence (CE-MPRAGE) was conducted after an intravenous injection of the contrast agent gadoteric acid (Dotarem, Guerbet, France). CEST acquisition was based on the steady-state approach proposed by Ref. [32] . In our implementation, a segmented 3D echo planar imaging (EPI) readout with three shots per partition was used [33] . In order to suppress the fat signal, a rectangular excitation pulse, with a duration of 2.4 ms, was used as proposed by Ref. [34] . The TR interval, consisting of a100 ms Gaussian RF pulse, crusher gradients and a partial EPI readout (echo train length = 26 ms), amounted to TR = 136 ms and an average B 1 power of 1 μT [35] . 
PET acquisition
18
F-FET was produced via nucleophilic 18 F-fluorination with a radiochemical purity greater than 98%, a specific radioactivity greater than 200 GBq/μmol and a radiochemical yield of about 60%, as described previously [36] . According to the German guidelines for brain tumour imaging using labelled amino acid analogue, all patients fasted for at least 4 h before the PET acquisition [37] . Dynamic PET scans from 0 to 50 min postinjection were performed after an intravenous injection of approximately 250 MBq of 18 F-FET. Attenuation correction was performed with a template-based approach using MRI [38] . PET data were reconstructed using an OP-OSEM3D algorithm with four subsets and 32 iterations where normalisation and attenuation, scatter, dead time and random corrections were included [39] . The reconstructed dynamic data set consisted of 16 time frames ( 
Data processing
All data processing and analyses were performed using MATLAB code developed in-house (The MathWorks, Inc., Natick, MA, USA), Python code (Python Software Foundation, version 2.7, available at http://www.python.org) and the software PMOD (version 3.7, PMOD Technologies, Ltd., Switzerland). Data co-registration was performed with the FLIRT tool from FSL [40, 41] using the APT-CEST image at 3.5 ppm as reference [42] .
Field maps
Field maps for B 0 correction of the CEST data were calculated from the multi-echo GRE data. Images were masked based on the magnitude data, and field maps were unwrapped using the algorithm from Ref. [43] .
CEST data processing B 0 field maps were used to correct the Z-spectrum for field shifts using a smoothing spline interpolation on a voxel-by-voxel basis. After correction, the data from the offsets between 14 and 7 ppm were fitted to the Henkelman two-pool magnetisation transfer (MT) model, as suggested for the extrapolated semisolid magnetisation transfer reference (EMR) method [44] [45] [46] [47] [48] .
In order to calculate the CEST-weighted images, two approaches were considered: magnetisation transfer ratio asymmetry (MTR asym ) and differences to the EMR (named using #). The MTR asym at 3.3 to 3.7 ppm was used, while EMR for the APT# and NOE# were calculated at 3.3 to 3.7 ppm and at −3.7 to −3.3 ppm, respectively.
Data analysis
A volume-of-interest (VOI) analysis was performed to compare the different CEST metrics with 18 F-FET PET data. Three VOIs were considered to evaluate the tumour region. One PET-based tumour VOI (FET-VOI) was defined as follows: a spherical background VOI was positioned in the hemisphere contralateral to the lesion in healthy brain tissue (volume of background VOI, 14.1 ml; 7220 voxels, 30-mm diameter). The tumour VOI was defined in the summed 18 F-FET PET image from 20 to 40 min post-injection by a 3D auto-contouring process using a tumourto-brain ratio (TBR) of 1.6 or more. This metric is widely used in 18 F-FET PET, and the cut-off value is based on a biopsycontrolled study of cerebral gliomas [7-9, 30, 49] . Two MRbased VOIs were manually defined: FLAIR-VOI, based on the image hyperintensities; and CE-MPRAGE-VOI, based on contrast-enhanced regions (Fig. 1) .
Statistical analysis of the TBR of the CEST metrics was performed against 18 F-FET data applying a non-parametric Wilcoxon test using SPSS (version 22.0; IBM Corp., Armonk, NY, USA). P values of 0.05 or less were considered statistically significant. In addition, the hot spots in the tumour area were localised in 18 F-FET PET and APT# and their distance was calculated.
Results
Figure 2 presents Z-spectra for a pixel in the tumour and for a pixel in normal-appearing white matter. The signal at 3.5 ppm is increased in the tumour voxel compared to the healthy tissue pixel. This increase is also visible in the difference to its corresponding EMR curve. In contrast, no peak was found in the downfield area of the Z-spectrum in healthy-appearing brain tissue. In this figure, it can also be seen that the EMR follows the conventional macromolecular pool for wide frequency offsets in the range of 14 to 7 ppm. Figures 1, 3 and 4 show the clinical and parametric images obtained for two subjects. Figure 1 shows a case with a tumour where the contrast-enhanced region did not correspond with the metabolically active area in PET. The contrastenhanced regions in the T 1 -weighted MRI also did not correspond with the FLAIR hyperintensities. In the MTR asym (Fig.  1g) , the tumour showed an increased value compared to healthy-appearing brain parenchyma. In the downfield APT# images, an increased intensity was observed in the metabolically active tumour area as defined by 18 F-FET PET, while the NOE# showed no differences between the tumour area and healthy-appearing brain tissue. In Fig. 3 , a case of a tumour with a necrotic area is presented. Here, the clinical data showed a contrast enhancement around the necrotic area, and a hyperintense signal in the FLAIR image. In the PET data, the metabolically active area surrounds the necrotic region. For the CEST data, increased MTR asym values were observed in the necrotic region, while in the EMR parametric images (NOE# and APT#), the necrotic region presented values near zero, suggesting a reduced effect of direct water and MT contributions. In Fig. 4 , a case of a tumour in the frontal lobe is presented. Here, the clinical data showed a contrast enhancement in the tumour region and a hyperintense signal in the FLAIR image. In the PET data, the metabolically active area has a larger extension when compared to the standard clinical data. For the CEST data, increased MTR asym values were observed in the tumour region. In the EMR parametric images, NOE# presented no signal changes, while APT# presented an increased signal in the tumour region with a different pattern to that of 18 F-FET. This example also illustrates the advantage of using 3D CEST as it enabled the full tumour extent to be evaluated. (Table 3) .
Discussion
The aim of this study was to compare different CEST metrics with amino acid PET in cerebral gliomas using the clinically established PET tracer, 18 F-FET, to examine the similarities/ differences between the two methods. Each modality has already shown its diagnostic potential, for example, for tumour grading or discrimination of radiation necrosis against tumour recurrence [9, 49, 50] . While 18 F-FET PET achieves a moderate accuracy of 77% for tumour grading [51] , APT has shown more promising data, with an area under the curve in receiver operating characteristic (ROC) analysis of 81-88% [22] . To the best of our knowledge, no study in the literature has ever compared 18 F-FET PET and APT. Thus, for the first time, this study investigates the relation between 18 F-FET PET-and CEST-related metrics in brain tumours using simultaneous MR-PET at 3 T and three-dimensional imaging.
In principle, 18 F-FET PET and APT are based on different biochemical and physiological mechanisms. 18 F-FET PET provides information about the expression of large amino acid transporter systems [L-type amino acid transporters 1 and 2 (LAT-1 and LAT-2)] that are more strongly expressed in brain tumours than in healthy tissue [52] . Consequently, an increased 18 F-FET signal is not necessarily related to increased protein synthesis or increased protein content, but to an increased expression of LAT transporters. In contrast, the APT signal is related to the peptides and mobile proteins, not to the total protein content [53] , as well as local modification of pH [54] . Our results present no relation between APT-CEST and 18 F-FET PET in the tumour region ( Table 2 ), suggesting that the expression of LAT transporters and the transfer of peptides and mobile proteins/change of pH is not strictly coupled. In addition, hotspot locations in 18 F-FET and APT differ (Table 3) , which suggests that both modalities could be used to further understand the increasingly important issue of tumour heterogeneity.
Several CEST metrics (MTR asym , NOE# and APT#) were calculated in this work using an irradiation power of 1 μT and compared with 18 F-FET PET. In the literature, most studies performed at 3 T use an effective power of 2 μT or higher [16-18, 22, 23, 50, 55] . The value of 2 μT is chosen in order to obtain a null contrast in the normal-appearing white matter using MTR asym [55] , once the contribution of NOE and APT signals cancel out in healthy tissue. However, at higher power, the influence of the macromolecular pool also increases [56] , resulting in APT-weighted images (MTR asym ) including MT contributions. Thus, in this work, an irradiation power of 1 μT was used in order to obtain close to the maximum APT contrast and to reduce the influence of the macromolecular pool, which was further corrected using the EMR model. Moreover, this methodology proved to be stable regarding the applied power and allowed NOE# contrast to also be obtained [46] [47] [48] . The origin of this signal is still under discussion [24] [25] [26] , and it has also been suggested that it could be linked to protein folding and structure [57] . Moreover, studies investigating NOE effects are often performed at higher field strengths (>3 T) [24] [25] [26] , which also influences the contrast.
In addition to various CEST metrics, different radiotracers are also available to measure amino acid transport, such as 18 F-FDOPA. This radiotracer was used non-simultaneously with two-dimensional CEST in Refs. [28, 29] . In these studies, the authors explored the CEST signal from amines at 3 ppm as a measure of pH using a saturation power of 6 μT. They found an elevated MTR asym signals in regions with elevated uptake of 18 F-FDOPA, but it was not quantified. Tissue pH and T 1 are potential confounding factors in the present work, as they influence the CEST contrast [16, 24, 54, 58, 59] . Regarding pH, an increased CEST signal can be associated to an alkalinisation of the tissue or an increased protein concentration that could not be disentangled in this work. However, imaging pH exclusively is beyond the scope of the presented work that focused on evaluating different CEST metrics in the metabolically active tumour area defined by 18 F-FET PET. With respect to T 1 , this is also a factor that can also influence CEST contrast [16] , [24] . In the tumour region, the increase in T 1 usually occurs simultaneously with an increase in water content, which may reduce T 1 influence in the CEST signal [16] . Further studies are needed to understand the relationship between CEST, 18 F-FET, pH, tumour extent, and hotspot locations.
Defining tumour extent is an important issue for patient assessment and treatment planning. With conventional MRI, this is usually based on the contrast-enhanced regions of T 1 weighted images [60] [61] [62] . Contrast-enhancement in MRI, however, indicates areas with a disrupted blood-brain barrier (BBB) that, on the one hand, are not specific for tumour tissue, and on the other hand may not detect the full extent of the tumour. In contrast, 18 F-FET uptake is independent of the BBB integrity [63] and allows a more specific delineation of tumour extent than contrast-enhanced MRI [30] . Thus, the results cannot be directly compared and often show discrepancies. For example, in the case of low-grade gliomas where the BBB is mostly intact, often no contrast enhancement is observed, although there is still an increased uptake of 18 F-FET [30] . Thus, the present study considers the 18 F-FET-positive regions to metabolically define the tumour regions. This approach is supported by the biopsy-controlled study of Ref. [30] . In the CEST literature, PET data are usually unavailable for comparison, and consequently, different studies present different strategies to delineate the tumour region, which may or may not be accurate. In Ref. [18] , ROIs were placed over the CE-MPRAGE or in FLAIR data when no contrast (Table 2) . By using 18 F-FET PET, the solid and metabolically active tumour tissue can be defined with high reliability; this presents an enormous advantage in the present study, compared to previous studies.
Three-dimensional acquisition is required in clinical applications in order to obtain whole-tumour imaging. In CEST studies, two-dimensional imaging is often used to avoid long acquisition times [24, 26, 64] . In the present study, a steadystate approach based on segmented three-dimensional EPI was used [32] to obtain fast full-brain coverage. Consequently, it was possible to acquire a single image in 18 s, without the use of parallel imaging due to hardware limitations (reduced number of receive channels). In our approach, we sampled the Z-spectrum with 70 points in 21 min, which is still rather long, but this could easily be reduced to about 10 min by employing parallel imaging. Nevertheless, if a simplified sampling scheme with less sampling offset is considered, as suggested in [21] , the measurement time could be reduced to 6 min.
The CEST imaging technique benefits from higher static magnetic fields (> 3 T) due to the increased spectral dispersion and increased signal-to-noise ratio. For that reason, the majority of the studies are performed at 7 T [20, 24, 32, 65] . However, no human MR-PET machine is currently available at 7 T.
The results obtained need to be confirmed in a larger and more diverse population of patients. Nevertheless, the methodology presented here can be combined with high-field methods [66] , pointing towards human MR-PETexperiments up to 9.4 Twhich would allow greater insights into tumour metabolism [67] .
Conclusions
For the first time, CEST imaging was compared with amino acid PET using 18 F-FET in a simultaneous MR-PET measurement. Based on the well-founded assumption that high 18 F-FET uptake reflects metabolically active tumours, our data suggest that APT-CEST provides substantially different information.
